ERIS — Eris Lifesciences Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹186.21bn
- IN₹208.96bn
- IN₹31.29bn
Annual cashflow statement for Eris Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 4,422 | 4,046 | 4,312 | 4,889 | 6,385 |
| Depreciation | |||||
| Non-Cash Items | -155 | 228 | 717 | 2,326 | 2,024 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,132 | -2,453 | -1,725 | 299 | -5,824 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 3,783 | 2,992 | 5,130 | 10,668 | 5,380 |
| Capital Expenditures | -1,210 | -8,414 | -1,292 | -1,550 | -2,969 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1,986 | -1,407 | -17,254 | 750 | -726 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3,196 | -9,821 | -18,545 | -800 | -3,695 |
| Financing Cash Flow Items | -33.2 | -234 | -876 | -3,826 | -1,933 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -447 | 6,880 | 13,798 | -8,813 | -3,135 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 140 | 51.5 | 382 | 1,055 | -1,450 |